TSMC Accelerates 2nm Expansion as AI Chip Demand Surges 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
Chainlink Launches CCIP 2.0 With Enhanced Cross-Chain Security 
OpenAI Investigates Rogue AI Agents After Data Leaks and Security Incidents 
RedotPay Completes Audits as Stablecoin Firm Advances U.S. IPO Plans 
Dubai’s connectivity remains strong in an uncertain world 
OpenAI, Anthropic CEOs Summoned to Australia AI Inquiry 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
DaVoice Sues Perplexity AI Over Trade Secrets 
OpenAI Agents Access U.S. Government Websites During Testing 
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 
Morgan Stanley Raises TD Synnex Price Target to $359 on Strong AI Demand 
Binance Expands MarsCoin With Tokenized SpaceX Share Rewards 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Add as a preferred source on Google
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
